In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Fate Therapeutics (FATE), with a price target of $12. The company’s shares opened today at $14.47.
White observed:
“Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 3Q18 fully diluted net cash estimate of $2.28/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.03/ share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 43.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fate Therapeutics with a $17.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.94 and a one-year low of $3.80. Currently, Fate Therapeutics has an average volume of 703.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
